KR102747348B1 - 경구 리파마이신 sv 조성물 - Google Patents

경구 리파마이신 sv 조성물 Download PDF

Info

Publication number
KR102747348B1
KR102747348B1 KR1020207014333A KR20207014333A KR102747348B1 KR 102747348 B1 KR102747348 B1 KR 102747348B1 KR 1020207014333 A KR1020207014333 A KR 1020207014333A KR 20207014333 A KR20207014333 A KR 20207014333A KR 102747348 B1 KR102747348 B1 KR 102747348B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
rifamycin
oral pharmaceutical
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014333A
Other languages
English (en)
Korean (ko)
Other versions
KR20200086285A (ko
Inventor
루이기 모로
루이기 마리아 롱고
Original Assignee
코스모 테크놀러지스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스모 테크놀러지스 리미티드 filed Critical 코스모 테크놀러지스 리미티드
Publication of KR20200086285A publication Critical patent/KR20200086285A/ko
Application granted granted Critical
Publication of KR102747348B1 publication Critical patent/KR102747348B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207014333A 2017-11-10 2018-11-07 경구 리파마이신 sv 조성물 Active KR102747348B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584226P 2017-11-10 2017-11-10
US62/584,226 2017-11-10
PCT/IB2018/058748 WO2019092614A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Publications (2)

Publication Number Publication Date
KR20200086285A KR20200086285A (ko) 2020-07-16
KR102747348B1 true KR102747348B1 (ko) 2024-12-31

Family

ID=64426987

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014333A Active KR102747348B1 (ko) 2017-11-10 2018-11-07 경구 리파마이신 sv 조성물

Country Status (17)

Country Link
US (3) US11564883B2 (https=)
EP (3) EP4438039A3 (https=)
JP (2) JP2021502382A (https=)
KR (1) KR102747348B1 (https=)
CN (1) CN111328279B (https=)
AR (1) AR114140A1 (https=)
AU (1) AU2018364617B2 (https=)
BR (1) BR112020009171A2 (https=)
CA (1) CA3078900A1 (https=)
DK (1) DK3706724T3 (https=)
ES (1) ES2989706T3 (https=)
FI (1) FI3706724T3 (https=)
IL (1) IL274414B2 (https=)
MX (1) MX2020004706A (https=)
PL (1) PL3706724T3 (https=)
WO (1) WO2019092614A1 (https=)
ZA (1) ZA202002726B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102198A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 内服固形剤
US20220280478A1 (en) * 2021-03-05 2022-09-08 Bausch Health Ireland, Limited Methods of using rifamycin sv for the treatment of sickle cell disease
EP4412588A1 (en) * 2021-10-05 2024-08-14 Cosmo Technologies Ltd An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
KR20080081351A (ko) 2006-01-04 2008-09-09 도꾜 메디칼 앤드 덴탈 유니버시티 간장 질환 치료제 및 간기능 개선제
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8741048B2 (en) 2011-08-30 2014-06-03 Brother Kogyo Kabushiki Kaisha Water-based ink for ink-jet recording and ink cartridge
IN2014DN06662A (https=) 2012-02-13 2015-05-22 Cosmo Technologies Ltd
WO2016003536A1 (en) 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same

Also Published As

Publication number Publication date
AR114140A1 (es) 2020-07-29
PL3706724T3 (pl) 2024-12-16
AU2018364617B2 (en) 2024-11-07
KR20200086285A (ko) 2020-07-16
EP4438039A3 (en) 2024-12-04
JP2021502382A (ja) 2021-01-28
MX2020004706A (es) 2020-09-07
RU2020119035A (ru) 2021-12-10
ES2989706T3 (es) 2024-11-27
WO2019092614A1 (en) 2019-05-16
US12036316B2 (en) 2024-07-16
IL274414B2 (en) 2024-08-01
CN111328279B (zh) 2023-04-14
CN111328279A (zh) 2020-06-23
US11564883B2 (en) 2023-01-31
CA3078900A1 (en) 2019-05-16
US20240398699A1 (en) 2024-12-05
DK3706724T3 (da) 2024-10-14
EP4431094A3 (en) 2024-11-20
EP3706724B1 (en) 2024-09-11
IL274414B1 (en) 2024-04-01
JP2023112076A (ja) 2023-08-10
ZA202002726B (en) 2024-09-25
FI3706724T3 (fi) 2024-10-14
AU2018364617A1 (en) 2020-05-07
EP3706724A1 (en) 2020-09-16
IL274414A (en) 2020-06-30
US20200281850A1 (en) 2020-09-10
RU2020119035A3 (https=) 2022-04-20
JP7651620B2 (ja) 2025-03-26
BR112020009171A2 (pt) 2020-11-03
EP4431094A2 (en) 2024-09-18
US20230135346A1 (en) 2023-05-04
EP4438039A2 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7651620B2 (ja) 経口リファマイシンｓｖ組成物
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20240058353A1 (en) Methods for treating gi tract disorders
DuPont Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases
HK1259347A1 (zh) 治疗结肠炎的方法
KR102624627B1 (ko) 지연 방출 데페리프론 정제 및 그의 사용 방법
KR20150132214A (ko) 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법
KR20170038810A (ko) 과민성 대장 증후군(ibs)의 재치료 방법
US20130115286A1 (en) Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract
CA2918004C (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20230116647A1 (en) Methods of treating covid-19 with rifaximin
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions
HK40036103B (en) Oral rifamycin sv compositions
HK40036103A (en) Oral rifamycin sv compositions
US20080159987A1 (en) Use of Rifaximin for the Treatment of Restless Legs Syndrome
EP4271385A1 (en) Methods of metabolizing metopimazine and its salts
US20080161337A1 (en) Use of Rifaximin for the Treatment of Chronic Prostatitis
MXPA05009025A (es) Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211006

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231211

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240822

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241125

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241219

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration